---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-046812"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:41:34.828370+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals selects CHDR for Phase I/IIa trial of Ketamir-2; recruitment starts Q1 2025

## Summary
- Trial site: The Centre for Human Drug Research (CHDR) in Leiden, Netherlands.
- Phase I in healthy subjects: initial safety/efficacy results expected H2 2025.
- Phase IIa planned Q4 2025 in diabetic neuropathy patients; efficacy results in H1 2026.
- Will use CHDR's PainCart® technology for early pain response measurement.
- Psychoactivity assessed separately; trial leverages unique early-efficacy capability.

## SEC filing metadata
- accession: 0001493152-24-046812
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224046812/0001493152-24-046812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224046812/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-046812
- JSON: https://secwatch.observer/filing/0001493152-24-046812.json
- Plain text: https://secwatch.observer/filing/0001493152-24-046812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.